STAGE IVB PROSTATE CANCER AJCC V8

This study tests a combination of three drugs (apalutamide, abiraterone, and prednisone) given after chemotherapy for men with advanced prostate cancer that has spread and hasn't been treated before. The goal is to see if this approach can lower PSA levels more effectively and al…

This early-phase trial tests a new treatment for men with advanced prostate cancer that no longer responds to hormone therapy. The treatment uses the patient's own immune cells, modified in a lab to recognize and attack cancer cells. The main goals are to find the safest dose and…

This early-stage trial tests a new drug (DS3201) combined with an immunotherapy (ipilimumab) in adults with advanced prostate, bladder, or kidney cancer that has spread. The goal is to find the safest dose and see if the combination can help control the disease. About 65 particip…

This study is for men whose prostate cancer has returned or spread to a few spots after initial treatment. It compares two types of radiation therapy given over a shorter time to see if they are safer and still effective. The goal is to control the disease with fewer side effects…

This study tests a drug called M1774 in 20 men with advanced prostate cancer that has a specific gene change (SPOP mutation) and has stopped responding to other treatments. The drug works by blocking certain enzymes that help cancer cells grow. The goal is to see if M1774 can shr…

This study tests the safety and effectiveness of combining the immunotherapy drug avelumab with other treatments (utomilumab, anti-OX40 antibody, and radiation) in 173 adults with advanced solid tumors that have spread. The goal is to find the best doses and see if these combinat…

This study tests a combination of two drugs—olaparib and radium-223—in men with a type of advanced prostate cancer that no longer responds to hormone therapy and has spread to the bones. The goal is to find the safest dose and see if the combo can slow the cancer's growth. About …

This study tests whether giving a radioactive drug (177-Lutetium-PSMA) before precise, high-dose radiation (SBRT) can better control prostate cancer that has returned in 1 to 5 spots after earlier treatment. About 93 adults with this type of recurrent cancer will receive either S…

This study looks at whether men whose metastatic prostate cancer has responded very well to hormone therapy can safely pause treatment. About 79 men will stop their medications under doctor guidance to see if their testosterone levels recover and they remain cancer-free for at le…

This study tests a treatment for prostate cancer that has come back and spread to a few other spots in the body. It combines hormone-blocking drugs (leuprolide, apalutamide, abiraterone) with precise, high-dose radiation (SBRT) to kill cancer cells. The goal is to see if this app…

This study is for men with a type of prostate cancer that no longer responds to hormone therapy and has spread to the bones. Researchers are using a special scan called PSMA PET to see if it can identify which patients will get the most benefit from a radiation therapy called Ra-…

This study tests a two-drug combination (niraparib and abiraterone) plus prednisone in men with advanced prostate cancer that has spread and has a specific change in the SPOP gene. The goal is to see if this treatment can shrink tumors or slow cancer growth. About 8 men will take…

This study tests a combination of three drugs (abiraterone, prednisone, and apalutamide) in 60 men whose prostate cancer has spread but who have not yet received hormone therapy. The goal is to see how long patients can stay on treatment and to measure cancer progression and side…

This study tests whether adding the drug relugolix to standard radiation therapy can delay cancer growth in men with prostate cancer that has spread to a few other spots in the body. Relugolix lowers testosterone, which some cancer cells need to grow. About 194 men will receive e…

This study tests whether adding rucaparib to standard enzalutamide treatment helps men with advanced prostate cancer that has spread and stopped responding to hormone therapy. About 61 participants will receive either the combination or enzalutamide alone. The goal is to see if t…

This study tests a special PET scan (68Ga-PSMA-11) to see if it can find and monitor prostate cancer more accurately than standard scans. About 141 men with prostate cancer that has come back or spread will get the scan. The goal is to help doctors choose the best treatment.

This study collects tissue and blood samples, along with medical information, from 1,600 people with various advanced cancers. Researchers will track these samples over time to learn how cancer changes and why some treatments stop working. The goal is to build a resource for futu…